Skip to main content
. 2013 Jun 24;67(8):759–767. doi: 10.1111/ijcp.12212

Figure 1.

Figure 1

Large glycaemic response (HbA1c reduction from baseline ≥ 1.0%)* in studies of saxagliptin as an add-on to another oral antihyperglycaemic drug. MET, metformin; SAXA 2.5, saxagliptin 2.5 mg once daily; SAXA 5, saxagliptin 5 mg once daily; SU, sulphonylurea (glyburide); TZD, thiazolidinedione (pioglitazone or rosiglitazone). n, overall number of patients randomised and treated. *Difference (95% CI) from placebo shown above bars